<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVES: Thirty seven vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> (VAD) patients were categorized into eight subtypes based on clinical, radiological, and pathogenetic features </plain></SENT>
<SENT sid="1" pm="."><plain>Cerebral <z:chebi fb="1" ids="35620">vasodilator</z:chebi> responses to <z:chebi fb="0" ids="27690">acetazolamide</z:chebi> were then compared with age-matched <z:mpath ids='MPATH_458'>normal</z:mpath> controls and <z:hpo ids='HP_0001297'>stroke</z:hpo> patients without <z:hpo ids='HP_0000726'>dementia</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: VAD results were compared with 42 <z:mpath ids='MPATH_458'>normals</z:mpath> and 19 cognitively intact <z:hpo ids='HP_0001297'>stroke</z:hpo> patients </plain></SENT>
<SENT sid="3" pm="."><plain>Regional cerebral <z:chebi fb="1" ids="35620">vasodilator</z:chebi> responses were quantitated utilizing <z:chebi fb="3" ids="49957">xenon</z:chebi> contrasted computed tomography measures of local cerebral blood flow (LCBF) before and after oral administration of <z:chebi fb="0" ids="27690">acetazolamide</z:chebi> </plain></SENT>
<SENT sid="4" pm="."><plain>LCBF changes (DeltaLCBF) before and after <z:chebi fb="0" ids="27690">acetazolamide</z:chebi> were calculated within cortical and subcortical, gray and white matter </plain></SENT>
<SENT sid="5" pm="."><plain>Clinical VAD subtypes were: type 1, multi-<z:mpath ids='MPATH_124'>infarct</z:mpath> <z:hpo ids='HP_0000726'>dementia</z:hpo> (MID); type 2, strategically placed <z:mpath ids='MPATH_124'>infarcts</z:mpath>; type 3, subcortical lacunar <z:mpath ids='MPATH_124'>infarcts</z:mpath>; type 4, <z:e sem="disease" ids="C0270786" disease_type="Disease or Syndrome" abbrv="">Binswanger</z:e>'s subcortical arteriosclerotic <z:hpo ids='HP_0002352'>leukoencephalopathy</z:hpo>; type 5, <z:e sem="disease" ids="C0751014" disease_type="Disease or Syndrome" abbrv="">subcortical infarctions</z:e> due to cerebral <z:hpo ids='HP_0000006'>autosomal dominant</z:hpo> <z:e sem="disease" ids="C0852949" disease_type="Disease or Syndrome" abbrv="">arteriopathy</z:e> with subcortical <z:mpath ids='MPATH_124'>infarcts</z:mpath> and <z:hpo ids='HP_0002352'>leukoencephalopathy</z:hpo> (CADASIL), inflammatory angitis, or <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo>; type 6, admixtures of above types; type 7, cerebral hemorrhagic lesions; and type 8, VAD combined with <z:e sem="disease" ids="C0002395" disease_type="Disease or Syndrome" abbrv="SDAT">Alzheimer's disease</z:e> (DAT) </plain></SENT>
<SENT sid="6" pm="."><plain>The group with subcortical VAD comprised types 3-5 </plain></SENT>
<SENT sid="7" pm="."><plain>The group with cortical VAD comprised the remainder (types 1, 2, and 6-8) </plain></SENT>
<SENT sid="8" pm="."><plain>Cerebral <z:chebi fb="1" ids="35620">vasodilator</z:chebi> responses were also compared between these two main groups </plain></SENT>
<SENT sid="9" pm="."><plain>Results: Cerebral <z:chebi fb="1" ids="35620">vasodilator</z:chebi> responses identified differences between the two main groups of VAD patients, those with cortical and those with <z:hpo ids='HP_0007123'>subcortical dementia</z:hpo> </plain></SENT>
<SENT sid="10" pm="."><plain>Leukoaraiosis was measurably greater in subcortical VAD compared with cortical VAD </plain></SENT>
<SENT sid="11" pm="."><plain>Among subcortical VAD patients, cortical LCBF increases after administration of <z:chebi fb="0" ids="27690">acetazolamide</z:chebi> were greater compared with cortical VAD and with <z:mpath ids='MPATH_458'>normal</z:mpath> controls </plain></SENT>
<SENT sid="12" pm="."><plain>CONCLUSIONS: <z:hpo ids='HP_0100543'>Cognitive impairments</z:hpo> in subcortical VAD are attributable to cortical disconnection syndromes </plain></SENT>
<SENT sid="13" pm="."><plain>This concept is supported by reduced perfusion in deactivated cortex </plain></SENT>
<SENT sid="14" pm="."><plain>In patients with subcortical VAD, deactivated cortical LCBF becomes promptly activated by <z:chebi fb="0" ids="27690">acetazolamide</z:chebi> resulting in marked cortical LCBF increases </plain></SENT>
<SENT sid="15" pm="."><plain>Leukoaraiosis is greater among VAD patients and leukoaraiosis contributes to cortical disconnections, confirmed by excessive cortical <z:chebi fb="1" ids="35620">vasodilator</z:chebi> responses to <z:chebi fb="0" ids="27690">acetazolamide</z:chebi> </plain></SENT>
</text></document>